Cite
Off-label use of chloroquine, hydroxychloroquine, azithromycin and lopinavir/ritonavir in COVID-19 risks prolonging the QT interval by targeting the hERG channel.
MLA
Zequn, Zheng, et al. “Off-Label Use of Chloroquine, Hydroxychloroquine, Azithromycin and Lopinavir/Ritonavir in COVID-19 Risks Prolonging the QT Interval by Targeting the HERG Channel.” European Journal of Pharmacology, vol. 893, Feb. 2021, p. N.PAG. EBSCOhost, https://doi.org/10.1016/j.ejphar.2020.173813.
APA
Zequn, Z., Yujia, W., Dingding, Q., & Jiangfang, L. (2021). Off-label use of chloroquine, hydroxychloroquine, azithromycin and lopinavir/ritonavir in COVID-19 risks prolonging the QT interval by targeting the hERG channel. European Journal of Pharmacology, 893, N.PAG. https://doi.org/10.1016/j.ejphar.2020.173813
Chicago
Zequn, Zheng, Wu Yujia, Qian Dingding, and Lian Jiangfang. 2021. “Off-Label Use of Chloroquine, Hydroxychloroquine, Azithromycin and Lopinavir/Ritonavir in COVID-19 Risks Prolonging the QT Interval by Targeting the HERG Channel.” European Journal of Pharmacology 893 (February): N.PAG. doi:10.1016/j.ejphar.2020.173813.